Short-chain fatty acids and intestinal inflammation in Multiple Sclerosis – Modulation of female susceptibility by microbial products?
Authors:
Preprint
- 7 October 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background. Multiple Sclerosis (MS) is an autoimmune-mediated disease of the central nervous system. Experimental data also suggest a role of intestinal microbiota and microbial products such as short-chain fatty acids (SCFA) in the pathogenesis of MS. A recent clinical study reported beneficial effects (mediated by immunomodulatory mechanisms) after oral administration of the SCFA propionate in MS patients. Based on available evidence, we aimed to investigate whether SCFA and the fecal inflammation marker calprotectin are altered in MS. Methods. 76 subjects (41 patients with relapsing-remitting MS and 35 age-matched controls) were investigated in this case-control study. All subjects underwent clinical assessment with established scales and provided fecal samples for a quantitative analysis of fecal SCFA and fecal calprotectin concentration. Fecal markers were compared between MS patients and controls, and were analyzed for an association with epidemiological as well as clinical parameters. Results. Median fecal calprotectin concentrations remained within normal range without any group-specific differences. Fecal SCFA showed a non-significant reduction in MS patients, whereas female subjects showed significantly reduced SCFA concentrations compared to male subjects. Conclusions. In our cohort of MS patients, we found no evidence of an active intestinal inflammation. As the vast majority of patients, however, was under immunotherapy, this might have affected the outcome measures. The sex-associated difference in fecal SCFA concentrations might at least partially explain female predominance in MS. Large-scale longitudinal studies including drug-naïve MS patients are required to determine the role of SCFA in MS and to distinguish between disease-immanent effects and those caused by the therapeutic regime.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory MechanismCell, 2020
- Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosisNeurochemistry International, 2019
- Short‐chain fatty acids: Bacterial messengers modulating the immunometabolism of T cellsEuropean Journal of Immunology, 2019
- Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sexJournal of Autoimmunity, 2018
- Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's diseaseParkinsonism & Related Disorders, 2018
- Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controlsParkinsonism & Related Disorders, 2016
- From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial MetabolitesCell, 2016
- Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small IntestineImmunity, 2015
- Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelinationNature, 2011
- A constipation scoring system to simplify evaluation and management of constipated patientsDiseases of the Colon & Rectum, 1996